{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:25:53Z","timestamp":1792211153060,"version":"4.4.0"},"reference-count":13,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2024,2,26]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1136\/ejhpharm-2024-004089","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:20:20Z","timestamp":1709731220000},"page":"94-97","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8433-8553","authenticated-orcid":false,"given":"Marianna","family":"Rivasi","sequence":"first","affiliation":[{"name":"Dipartimento Farmaceutico Interaziendale, Azienda Unit\u00e0 Sanitaria Locale di Modena, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Porretta Serapiglia","sequence":"additional","affiliation":[{"name":"Dipartimento Farmaceutico Interaziendale, Azienda Unit\u00e0 Sanitaria Locale di Modena, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Medici","sequence":"additional","affiliation":[{"name":"Dipartimento Farmaceutico Interaziendale, Azienda Unit\u00e0 Sanitaria Locale di Modena, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ricchi","sequence":"additional","affiliation":[{"name":"Dipartimento Farmaceutico Interaziendale, Azienda Unit\u00e0 Sanitaria Locale di Modena, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"2025122321350570000_33.1.94.1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12254-016-0304-2","article-title":"Extravasation emergencies: state-of-the-art management and progress in clinical research","volume":"9","author":"Pluschnig","year":"2016","journal-title":"Memo"},{"key":"2025122321350570000_33.1.94.2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/1078155220950005","article-title":"Monoclonal antibody extravasations: two case reports and literature review","volume":"27","author":"Rodr\u00edguez-Alarc\u00f3n","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2025122321350570000_33.1.94.3","first-page":"167","article-title":"Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines on behalf of the ESMO guidelines working group","volume":"23","author":"Fidalgo","year":"2012","journal-title":"ESMO Updat Clin Pract Guidel"},{"key":"2025122321350570000_33.1.94.4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025122321350570000_33.1.94.5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jdv.13164","article-title":"T-DM1 extravasation: first description","volume":"30","author":"Sibaud","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122321350570000_33.1.94.6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JOP.2016.020198","article-title":"Skin necrosis after ado-trastuzumab emtansine extravasation","volume":"13","author":"Shafaee","year":"2017","journal-title":"J Oncol Pract"},{"key":"2025122321350570000_33.1.94.7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jcpt.13148","article-title":"Extravasation of an antibody-drug conjugate: a case report of epidermal necrosis after trastuzumab-emtamsine extravasation","volume":"45","author":"Sallevelt","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"2025122321350570000_33.1.94.8","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.101"},{"key":"2025122321350570000_33.1.94.9","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1111\/jdv.16502","article-title":"Demyelinating neuropathy and local toxicity caused by extravasated brentuximab vedotin","volume":"34","author":"Hoffmann","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122321350570000_33.1.94.10","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15751","article-title":"Brentuximab extravasation injury in a patient with mycosis fungoides with large cell transformation","volume":"35","author":"Kim","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025122321350570000_33.1.94.11","first-page":"10781552231178674","article-title":"Extravasation of monoclonal antibodies commonly used in oncology: classification, management and the role of the pharmacist","volume":"24","author":"Bauters","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"2025122321350570000_33.1.94.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh214"},{"key":"2025122321350570000_33.1.94.13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1078155217690924","article-title":"Pharmacological management of anticancer agent extravasation: a single institutional guideline","volume":"24","author":"Kimmel","year":"2018","journal-title":"J Oncol Pharm Pract"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T05:35:16Z","timestamp":1766554516000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/ejhpharm-2024-004089"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004089","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]}}}